Glaukos Corp (NYSE:GKOS) has been given an average recommendation of “Buy” by the ten brokerages that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $73.29.
A number of research firms have commented on GKOS. BTIG Research restated a “hold” rating on shares of Glaukos in a research note on Wednesday, May 22nd. Wells Fargo & Co restated a “buy” rating on shares of Glaukos in a research note on Wednesday, March 20th. Zacks Investment Research lowered German American Bancorp. from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, BMO Capital Markets raised their price objective on goeasy from C$55.00 to C$60.00 in a research note on Thursday, May 9th.
Shares of NYSE GKOS traded down $1.62 during trading hours on Friday, reaching $75.46. 12,352 shares of the stock were exchanged, compared to its average volume of 325,871. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -204.51 and a beta of 1.61. The company has a quick ratio of 6.23, a current ratio of 6.72 and a debt-to-equity ratio of 0.07. Glaukos has a 52 week low of $36.89 and a 52 week high of $83.14. The company’s fifty day simple moving average is $72.27.
Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.08. Glaukos had a negative return on equity of 6.90% and a negative net margin of 5.93%. The company had revenue of $54.03 million for the quarter, compared to analyst estimates of $50.13 million. On average, research analysts predict that Glaukos will post -0.3 EPS for the current fiscal year.
In other news, CFO Joseph E. Gilliam sold 2,603 shares of Glaukos stock in a transaction on Monday, May 13th. The stock was sold at an average price of $65.14, for a total value of $169,559.42. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 17,500 shares of company stock worth $1,251,929. Corporate insiders own 8.70% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of GKOS. Prudential Financial Inc. lifted its stake in Glaukos by 45.7% during the fourth quarter. Prudential Financial Inc. now owns 4,560 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 1,430 shares during the last quarter. First Trust Advisors LP lifted its stake in Glaukos by 8.5% during the fourth quarter. First Trust Advisors LP now owns 104,413 shares of the medical instruments supplier’s stock worth $5,865,000 after purchasing an additional 8,168 shares during the last quarter. California Public Employees Retirement System bought a new stake in Glaukos in the fourth quarter valued at $2,343,000. BlackRock Inc. lifted its stake in Glaukos by 6.3% in the fourth quarter. BlackRock Inc. now owns 2,563,895 shares of the medical instruments supplier’s stock valued at $144,014,000 after buying an additional 151,304 shares during the last quarter. Finally, Raymond James & Associates lifted its stake in Glaukos by 21.2% in the fourth quarter. Raymond James & Associates now owns 18,449 shares of the medical instruments supplier’s stock valued at $1,036,000 after buying an additional 3,222 shares during the last quarter. Institutional investors own 95.78% of the company’s stock.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.